CN110151854A - Rush digestion composition, preparation method and application containing longan total phenol extract - Google Patents
Rush digestion composition, preparation method and application containing longan total phenol extract Download PDFInfo
- Publication number
- CN110151854A CN110151854A CN201910444716.3A CN201910444716A CN110151854A CN 110151854 A CN110151854 A CN 110151854A CN 201910444716 A CN201910444716 A CN 201910444716A CN 110151854 A CN110151854 A CN 110151854A
- Authority
- CN
- China
- Prior art keywords
- composition
- longan
- total phenol
- preparation
- curcumin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 title claims abstract description 107
- 235000000235 Euphoria longan Nutrition 0.000 title claims abstract description 88
- 239000000203 mixture Substances 0.000 title claims abstract description 76
- 239000000284 extract Substances 0.000 title claims abstract description 57
- 238000002360 preparation method Methods 0.000 title claims abstract description 24
- 230000029087 digestion Effects 0.000 title claims abstract description 23
- 244000139609 Euphoria longan Species 0.000 title 1
- 240000001008 Dimocarpus longan Species 0.000 claims abstract description 90
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 claims abstract description 78
- 239000004148 curcumin Substances 0.000 claims abstract description 40
- 235000012754 curcumin Nutrition 0.000 claims abstract description 40
- 229940109262 curcumin Drugs 0.000 claims abstract description 40
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 claims abstract description 40
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 claims abstract description 34
- 235000010443 alginic acid Nutrition 0.000 claims abstract description 24
- 229920000615 alginic acid Polymers 0.000 claims abstract description 24
- 150000001720 carbohydrates Chemical class 0.000 claims abstract description 24
- 239000000783 alginic acid Substances 0.000 claims abstract description 22
- 229960001126 alginic acid Drugs 0.000 claims abstract description 22
- 150000004781 alginic acids Chemical class 0.000 claims abstract description 22
- 150000003839 salts Chemical class 0.000 claims abstract description 21
- 239000002608 ionic liquid Substances 0.000 claims abstract description 17
- 150000003053 piperidines Chemical class 0.000 claims abstract description 17
- 201000006549 dyspepsia Diseases 0.000 claims abstract description 15
- 230000002496 gastric effect Effects 0.000 claims abstract description 14
- 238000000605 extraction Methods 0.000 claims description 33
- 239000000243 solution Substances 0.000 claims description 23
- 239000006228 supernatant Substances 0.000 claims description 19
- -1 Phenylpiperidines bromide Chemical class 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 15
- 239000003480 eluent Substances 0.000 claims description 13
- 239000007788 liquid Substances 0.000 claims description 12
- 239000000843 powder Substances 0.000 claims description 11
- XPDWGBQVDMORPB-UHFFFAOYSA-N trifluoromethane acid Natural products FC(F)F XPDWGBQVDMORPB-UHFFFAOYSA-N 0.000 claims description 11
- 239000000706 filtrate Substances 0.000 claims description 10
- 238000000746 purification Methods 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 9
- 229920001542 oligosaccharide Polymers 0.000 claims description 9
- 150000002482 oligosaccharides Chemical class 0.000 claims description 9
- 238000000926 separation method Methods 0.000 claims description 9
- 229940079593 drug Drugs 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 230000002265 prevention Effects 0.000 claims description 7
- 239000002904 solvent Substances 0.000 claims description 7
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical group CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 6
- 239000007864 aqueous solution Substances 0.000 claims description 6
- 230000007812 deficiency Effects 0.000 claims description 6
- 239000007924 injection Substances 0.000 claims description 6
- 238000002347 injection Methods 0.000 claims description 6
- 238000002386 leaching Methods 0.000 claims description 6
- 239000000661 sodium alginate Substances 0.000 claims description 6
- 235000010413 sodium alginate Nutrition 0.000 claims description 6
- 229940005550 sodium alginate Drugs 0.000 claims description 6
- 230000001476 alcoholic effect Effects 0.000 claims description 5
- 238000001035 drying Methods 0.000 claims description 5
- 230000001737 promoting effect Effects 0.000 claims description 5
- 238000003756 stirring Methods 0.000 claims description 5
- 239000003337 fertilizer Substances 0.000 claims description 4
- 230000009854 mucosal lesion Effects 0.000 claims description 4
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 4
- AEMOLEFTQBMNLQ-SYJWYVCOSA-N (2s,3s,4s,5s,6r)-3,4,5,6-tetrahydroxyoxane-2-carboxylic acid Chemical group O[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H]1O AEMOLEFTQBMNLQ-SYJWYVCOSA-N 0.000 claims description 3
- 230000000857 drug effect Effects 0.000 claims description 3
- 150000002148 esters Chemical class 0.000 claims description 3
- 239000012467 final product Substances 0.000 claims description 3
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- 229940072056 alginate Drugs 0.000 claims description 2
- 239000011259 mixed solution Substances 0.000 claims description 2
- 229910052698 phosphorus Inorganic materials 0.000 claims description 2
- 239000011574 phosphorus Substances 0.000 claims description 2
- 238000009210 therapy by ultrasound Methods 0.000 claims description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 18
- 150000008442 polyphenolic compounds Chemical class 0.000 abstract description 15
- 235000013824 polyphenols Nutrition 0.000 abstract description 15
- 238000011084 recovery Methods 0.000 abstract description 10
- 210000002784 stomach Anatomy 0.000 abstract description 10
- 231100000331 toxic Toxicity 0.000 abstract description 5
- 230000002588 toxic effect Effects 0.000 abstract description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 22
- 230000000052 comparative effect Effects 0.000 description 16
- 235000019441 ethanol Nutrition 0.000 description 14
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 8
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 6
- 210000000813 small intestine Anatomy 0.000 description 6
- 206010000060 Abdominal distension Diseases 0.000 description 5
- 206010012735 Diarrhoea Diseases 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- FGXWKSZFVQUSTL-UHFFFAOYSA-N domperidone Chemical compound C12=CC=CC=C2NC(=O)N1CCCN(CC1)CCC1N1C2=CC=C(Cl)C=C2NC1=O FGXWKSZFVQUSTL-UHFFFAOYSA-N 0.000 description 5
- 229960001253 domperidone Drugs 0.000 description 5
- 229960004085 mosapride Drugs 0.000 description 5
- YPELFRMCRYSPKZ-UHFFFAOYSA-N 4-amino-5-chloro-2-ethoxy-N-({4-[(4-fluorophenyl)methyl]morpholin-2-yl}methyl)benzamide Chemical compound CCOC1=CC(N)=C(Cl)C=C1C(=O)NCC1OCCN(CC=2C=CC(F)=CC=2)C1 YPELFRMCRYSPKZ-UHFFFAOYSA-N 0.000 description 4
- 238000010828 elution Methods 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 230000008092 positive effect Effects 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000007613 environmental effect Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 229940074391 gallic acid Drugs 0.000 description 3
- 235000004515 gallic acid Nutrition 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000008855 peristalsis Effects 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 230000035479 physiological effects, processes and functions Effects 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000008929 regeneration Effects 0.000 description 3
- 238000011069 regeneration method Methods 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- KKAJSJJFBSOMGS-UHFFFAOYSA-N 3,6-diamino-10-methylacridinium chloride Chemical compound [Cl-].C1=C(N)C=C2[N+](C)=C(C=C(N)C=C3)C3=CC2=C1 KKAJSJJFBSOMGS-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 244000273928 Zingiber officinale Species 0.000 description 2
- 235000006886 Zingiber officinale Nutrition 0.000 description 2
- 238000006664 bond formation reaction Methods 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 239000000498 cooling water Substances 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 230000035622 drinking Effects 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 235000008397 ginger Nutrition 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 235000008216 herbs Nutrition 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 230000031700 light absorption Effects 0.000 description 2
- 239000007791 liquid phase Substances 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 239000003595 mist Substances 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000012488 sample solution Substances 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 238000001694 spray drying Methods 0.000 description 2
- 239000012086 standard solution Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000002699 waste material Substances 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- PAMIQIKDUOTOBW-UHFFFAOYSA-N 1-methylpiperidine Chemical class CN1CCCCC1 PAMIQIKDUOTOBW-UHFFFAOYSA-N 0.000 description 1
- LLSKXGRDUPMXLC-UHFFFAOYSA-N 1-phenylpiperidine Chemical class C1CCCCN1C1=CC=CC=C1 LLSKXGRDUPMXLC-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 241001539473 Euphoria Species 0.000 description 1
- 206010015535 Euphoric mood Diseases 0.000 description 1
- 206010019909 Hernia Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000007443 Neurasthenia Diseases 0.000 description 1
- 241001529246 Platymiscium Species 0.000 description 1
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 1
- 206010051373 Wound haemorrhage Diseases 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- HEBKCHPVOIAQTA-NGQZWQHPSA-N d-xylitol Chemical compound OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000003979 granulating agent Substances 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- DLRVVLDZNNYCBX-RTPHMHGBSA-N isomaltose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-RTPHMHGBSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 210000001187 pylorus Anatomy 0.000 description 1
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 239000002893 slag Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000005418 vegetable material Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/734—Alginic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/77—Sapindaceae (Soapberry family), e.g. lychee or soapberry
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Molecular Biology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The present invention is about a kind of longan extractive composition, composition, preparation method and application are digested especially with regard to a kind of rush containing longan total phenol extract, the rush digestion composition includes longan total phenol extract, the oligomeric saccharide complex of curcumin phosplate and alginic acid or its salt；Wherein, the longan total phenol extract is so that the ethanol water containing piperidines ionic liquid extracts longan peel and obtains.In longan total phenol extract of the invention Polyphenols content up to 92wt% to higher, longan pericarp total phenol recovery rate up to 35mg/g to higher; the rush digestion composition has the effects that excellent protection stomach lining, improves gastrointestinal motivity, improves indigestion; toxic side effect is small, and safety is higher.
Description
Technical field
The present invention disappears about a kind of longan extractive composition especially with regard to a kind of rush containing longan total phenol extract
Change composition, preparation method and application.
Background technique
Euphoria Sapindaceae longan platymiscium, is the local product fruits of south China.Longan fresh food quality is sharp and clear, and taste is clear
Sweet tea, it is full of nutrition, there are the multiple efficacies such as tonifying heart and spleen, nourishing blood and tranquilization, moistening skin beautifying, anaemia can be treated, palpitaition, insomnia, be good for
Forget, neurasthenia and after being ill, the diseases such as postpartum physical decline.The shell skin of longan pericarp system longan pulp, it is bitter, puckery, it is mild-natured, there is row
The effect of gas dissipating bind, hemostasis, eliminating dampness, cures mainly hernia, wound hemorrhage, underarm odor, wet sore etc..Modern pharmacological research proves, longan pericarp
Extract has hypoglycemic, anti-oxidant, anticancer, wound healing isoreactivity.Due to not comprehensively utilized, the dragon wasted every year
Therefore eye shell, extracts utilization to longan pericarp in terms of hundreds of tons, the economic value for improving longan has important meaning
Justice.
The disclosure of background above technology contents is only used for auxiliary and understands inventive concept and technical solution of the invention, not
The prior art for necessarily belonging to present patent application shows above content in the applying date of present patent application in no tangible proof
In the case where having disclosed, above-mentioned background technique should not be taken to the novelty and creativeness of evaluation the application.
Summary of the invention
The rush digestion composition that the purpose of the present invention is to provide a kind of containing longan total phenol extract, preparation method and
Using Polyphenols content is up to 92wt% to higher, longan pericarp total phenol recovery rate is reachable in longan total phenol extract of the invention
35mg/g is to higher, and the rush digestion composition has excellent protection stomach lining, improves gastrointestinal motivity, improves indigestion etc.
Effect, toxic side effect is small, and safety is higher.
The technical solution that the present invention is taken to achieve the above object are as follows:
[1] a kind of rush digests composition, and the composition includes:
Longan total phenol extract；
The oligomeric saccharide complex of curcumin phosplate；And
Alginic acid or its salt；
Wherein, the longan total phenol extract is to extract longan peel with the ethanol water containing piperidines ionic liquid
And it obtains.
In order to more fully show the present invention, in present invention content and preferred embodiment, institute is additionally provided
The preparation method for promoting the longan total phenol extract in digestion composition is stated, an at least step for following step is specifically included:
One extraction step: being to mix fresh longan pericarp dry powder with the ethanol water containing piperidines ionic liquid
Even, extraction, filtering obtain filtrate；
One separating step: being to be separated by solid-liquid separation the filtrate, muddy portion's fertilizer and/or feed, obtains supernatant；
One purification step: being that the supernatant is carried out column chromatographic purifying to obtain eluent；
One concentration step: being by eluent concentration, drying to obtain longan total phenol extract.
In the present application content and preferred embodiment, in the extraction step, the fresh longan pericarp dry powder is
The dry powder of 20~200 mesh gained is crossed after dry, pulverize after the cleaning of fresh longan pericarp.
In the present application content and preferred embodiment, in the extraction step, ethyl alcohol in the ethanol water
Content be 21~28wt%.
In the present application content and preferred embodiment, in the extraction step, the piperidines ionic liquid is
N- butyl-N- methyl piperidine bromide and bis- (fluoroform sulphonyl) inferior amine salts of N- butyl-N- methyl piperidine.
It is described in the ethanol water in the extraction step in the present application content and preferred embodiment
The content of N- butyl-N- methyl piperidine bromide is 1.25~1.3wt%, preferably 1.28~1.30wt%；N- butyl-the N-
The content of bis- (fluoroform sulphonyl) inferior amine salts of methyl piperidine is 0.25~0.26wt%, preferably 0.256~0.26wt%.
In the present application content and preferred embodiment, in the extraction step, the fresh longan pericarp dry powder with
The solid-liquid ratio of ethanol water containing piperidines ionic liquid is 1:35~45, g/mL；Preferably 1:40~42, g/mL.
In the present application content and preferred embodiment, in the extraction step, the extracting condition is: extraction temperature
Degree is 18~22 DEG C, extraction time is 30min~filter residue is taken to repeat to extract for 24 hours, after filtering, merging filtrate after extraction 3~5 times.
In the present application content and preferred embodiment, in the separating step, the mode of the separation of solid and liquid can
To stand and/or being centrifuged the filtrate to realize and be separated by solid-liquid separation.
It is described to stand to be not higher than 20 in the separating step in the present application content and preferred embodiment
24~96h is stood at a temperature of DEG C.
In the present application content and preferred embodiment, in the separating step, the centrifugation is not higher than 15
At a temperature of DEG C with 2000r/min to it is higher, preferably with 5000~20000r/min revolving speed be centrifuged 1min~2h.
In the present application content and preferred embodiment, in the purification step, with the institute in the extraction step
It states the ethanol water containing piperidines ionic liquid and elutes the supernatant.
In the present application content and preferred embodiment, in the purification step, the condition of the column chromatographic purifying
Be: loading rate is 2.2~4.2BV/h, and the flow velocity of the eluent is 2.8~6.0BV/h, and elution time is 30min~3h.
In the present application content and preferred embodiment, in the purification step, the concentration, drying are will be described
Extract eluent 35~45 DEG C 10~50KPa of vacuum degree, heating of bath temperature and under conditions of 1~10 DEG C of cooling water temperature into
Row is concentrated under reduced pressure, and obtained phegma is spray-dried, the longan total phenol extract based on polymer polyphenol is obtained.
In the present invention, to contain the ethanol water of specific composition and component piperidines ionic liquid as leaching liquor pair
Fresh longan pericarp dry powder is extracted, and the muddy portion of leaching liquor can prepare fertilizer and/or feed to increase the output value, through column layer
The supernatant of analysis purifying leaching liquor simultaneously obtains eluent with the elution of the ethanol water of the above-mentioned ionic liquid containing piperidines, dense
Contracting, the dry eluent are to obtain longan total phenol extract, and the method for above-mentioned preparation longan total phenol extract is easy in the application
It is easy, the muddy part of longan pericarp extracting solution can separately processing and utilization, increase industrial output value, it is more in longan total phenol extract
The content of phenols up to 92wt% to higher, and longan pericarp total phenol recovery rate up to 35mg/g to higher, in longan pericarp
The extraction efficiency of total phenol is very high, greatly improves the economic value of longan pericarp regeneration, in addition, higher purity and mentioning
Take rate that can also assign the efficient physiology effect of longan total phenol extract and medical value.
In the present application content and preferred embodiment, the curcumin monophosphate promoted in digestion composition
The oligomeric saccharide complex of ester is the compound for being obtained by mixing curcumin phosplate and oligosaccharide.
In the present application content and preferred embodiment, structural formula such as formula (1) institute of the curcumin phosplate
Show:
In the present application content and preferred embodiment, the oligosaccharide can be selected from sucrose, maltose, lactose, fibre
Tie up disaccharides, trehalose, raffinose, oligofructose, at least one of xylo-oligosaccharide, isomalto-oligosaccharide and cyclodextrin.
In order to more fully show the present invention, in present invention content and preferred embodiment, institute is additionally provided
The preparation method for promoting the oligomeric saccharide complex of curcumin phosplate in digestion composition is stated, the preparation method can be known normal
Any means in knowledge technology, therefore the application only enumerates but is not limited to following methods:
Obtain the oligomeric sugar aqueous solution of 1~10 DEG C, 10~35wt%；
Obtain the alcoholic solution of 1~10 DEG C, the curcumin phosplate of 3~8wt%；
Curcumin phosplate solution is injected in oligosaccharide solution under stirring；
It is spray-dried immediately after the completion of injection up to the oligomeric saccharide complex of water-soluble curcumin.
In present invention content and preferred embodiment, the stirring condition is 180~195r/min.
In present invention content and preferred embodiment, the injection rate is 3~5mL/min.
In present invention content and preferred embodiment, in the alcoholic solution content of ethyl alcohol be 30~
50%.
In present invention content and preferred embodiment, the spray drying condition is: inlet air temperature 215~
220 DEG C, 65~70 DEG C of leaving air temp, negative pressure of vacuum≤- 0.06Mpa, product moisture≤1.0%.
In the application, the curcumin phosplate, which is dissolved in alcohol, forms solution, and the solution is molten in inflow oligosaccharide
When in liquid, due to the reduction of alcohol concentration, curcumin phosplate is micro- with nanoscale in the conversion process of liquid phase and solid phase
Size separation goes out, and at this moment, the group in group and oligosaccharide in curcumin phosplate passes through spray with hydrogen bond formation physical bond
Mist is dry and solidifies, and forms the oligomeric saccharide complex of water-soluble curcumin phosplate, the ginger in this solid composite dispersion
Flavine phosplate solubility significantly improves.
At least one of in present invention content and preferred embodiment, the alginic acid or its salt satisfaction are following:
The alginic acid or its salt are prepared by brown alga；
The alginic acid or its salt are straight chain type；
Beta-D-mannuronic acid unit/α-L- guluronic units molar ratio=1.5 in the alginic acid or its salt；
The alginate is sodium alginate.
In summary of the invention and preferred embodiment of the invention, the rush digestion composition includes occupying the composition weight
Measure following components of percentage:
The longan total phenol extract of -10.00~99.98wt%；
The oligomeric saccharide complex of curcumin phosplate of -0.01~45.00wt%；And
The alginic acid of -0.01~45.00wt% or its salt.
In summary of the invention and preferred embodiment of the invention, the rush digestion composition, which preferably includes, occupies described group
Following components of polymer weight percentage:
The longan total phenol extract of -10.00~99.98wt%；
The oligomeric saccharide complex of curcumin phosplate of -0.01~45.00wt%；And
The alginic acid of -0.01~45.00wt% or its salt.
In summary of the invention and preferred embodiment of the invention, rush digestion composition more preferably include occupy it is described
Following components of composition weight percentage:
The longan total phenol extract of -50.00~99.98wt%；
The oligomeric saccharide complex of curcumin phosplate of -0.01~25.00wt%；And
The alginic acid of -0.01~25.00wt% or its salt.
In summary of the invention and preferred embodiment of the invention, rush digestion composition most preferably include occupy it is described
Following components of composition weight percentage:
The longan total phenol extract of -60.00~90.00wt%；
The oligomeric saccharide complex of curcumin phosplate of -5.00~20.00wt%；And
The alginic acid of -5.00~20.00wt% or its salt.
The longan total phenol extract that the present invention provides a kind of based on polymer polyphenol and including the longan total phenol
The rush of extract, the oligomeric saccharide complex of curcumin phosplate and alginic acid or its salt digest composition, it is provided by the invention with
Rush digestion composition based on longan total phenol extract has positive effect to enterogastric peristalsis, has protection stomach lining, improves stomach
Power improves the effects of indigestion, therefore the drugs such as domperidone, mosapride citrate can be replaced to play its promotion with it
Promote digestion, is suitable for preventing and/or treating the diseases such as gastrointestinal motivity deficiency, abdominal distension diarrhea, indigestion, further, since
Plant longan of the used primary raw material longan total phenol extract from integration of drinking and medicinal herbs, therefore toxic side effect is small, safety is more
Height extracts total phenol using longan pericarp, extends the application value of longan, is not only conducive to environmental protection, reduces waste pollution, and
And the processing cost of longan pericarp is reduced, realize the huge proliferation of economic benefit.
[2] preparation method of item [1] described composition, comprising the following steps:
It disperses alginic acid or its salt in solvent, is prepared into the solution that concentration is 3wt%；It is oligomeric to sequentially add curcumin
Saccharide complex and longan total phenol extract, mixed solution ultrasonic treatment 1h, low temperature be concentrated into density between 1.001~
1.300g/mL to obtain the final product.
In summary of the invention and preferred embodiment of the invention, the solvent includes water and organic solvent, and organic solvent can
Select ethyl alcohol or its aqueous solution, methanol or its aqueous solution, ethyl acetate or its aqueous solution；The preferred water of solvent.
The present invention provides one kind based on longan total phenol extract and includes the oligomeric saccharide complex of curcumin phosplate
Composition is digested with the rush of alginic acid or its salt, preparation method is first to disperse alginic acid or its salt in solvent, then
The oligomeric saccharide complex of curcumin is added and longan total phenol extract is uniformly mixed, low temperature is concentrated to obtain the final product.Rush digestion of the present invention
Composition has positive effect to enterogastric peristalsis, has the effects that protect stomach lining, improves gastrointestinal motivity, improves indigestion, because
This can replace the drugs such as domperidone, mosapride citrate play its promoting digestion with it, be suitable for prevention and/or
Treat the diseases such as gastrointestinal motivity deficiency, abdominal distension diarrhea, indigestion.
[3] a kind of pharmaceutical composition for promoting digestion, described pharmaceutical composition include described group of a effective amount of item of drug effect [1]
Close object.
In summary of the invention and preferred embodiment of the invention, described pharmaceutical composition can be added by item [1] composition
It is prepared after adding pharmaceutic adjuvant, the optional Autoadhesive of the pharmaceutic adjuvant, lubricant, glidant, disintegrating agent, granulating agent, packet
One of clothing agent, wetting agent, solvent, suspending agent, flavoring agent are a variety of, and the addition of the pharmaceutic adjuvant can refer to the prior art
The technology having disclosed, will not repeat them here.
In summary of the invention and preferred embodiment of the invention, described pharmaceutical composition can oral administration, parenterally give
Medicine, sucking spray delivery, rectally, intranasal administration, sublingual administration, administration, cutaneous penetration or drug delivery implant in cheek.
In summary of the invention and preferred embodiment of the invention, described pharmaceutical composition can be made into be suitable for by it is required to
The dosage form that medicine approach administers to a patient, for example, it is injection, capsule, tablet, pulvis, granule, lozenge, syrup, suspending agent, molten
Liquor, emulsion, suppository.
[4] application of item [1] described composition, the application includes but is not limited to:
The composition is preventing and/or is treating the application in gastrointestinal motivity deficiency；And/or
Application of the composition in preparation prevention and/or the treatment insufficient pharmaceutical preparation of gastrointestinal motivity；And/or
The composition is preventing and/or is treating the application in mucosal lesion；And/or
Application of the composition in the preparation of preparation prevention and/or treatment mucosal lesion drug；And/or
The composition is preventing and/or is treating the application in indigestion；And/or
The composition prevents and/or treats the application in dyspeptic pharmaceutical preparation in preparation.
Composition pair containing longan total phenol extract, curcumin phosplate oligomeric saccharide complex and alginic acid or its salt
Enterogastric peristalsis has positive effect, has the effects that protect stomach lining, improves gastrointestinal motivity, improves indigestion, therefore can be with it
It is played instead of drugs such as domperidone, mosapride citrates and promotes digestion, is suitable for preventing and/or treating stomach
It is short of power, the diseases such as abdominal distension diarrhea, indigestion.
The invention has the benefit that
In the application, to contain the ethanol water of specific composition and component piperidines ionic liquid as leaching liquor to new
Fresh longan pericarp dry powder is extracted, and longan total phenol extract, institute is prepared with the supernatant of above-mentioned solution elution leaching liquor
The content of Polyphenols in extract is stated up to 92wt% to higher, longan pericarp total phenol recovery rate up to 35mg/g to higher, to dragon
The extraction efficiency of total phenol is very high in eye shell, greatly improves the economic value of longan pericarp regeneration, higher purity and
Recovery rate can also assign the efficient physiology effect of longan total phenol extract and medical value；It is of the invention with the total phenol extraction of longan
Object is main composition and digests composition to intestines containing the rush of the oligomeric saccharide complex of curcumin phosplate and alginic acid or its salt
Peristole has positive effect, has the effects that excellent protection stomach lining, improves gastrointestinal motivity, improves indigestion, therefore can
It replaces the drugs such as domperidone, mosapride citrate to play it with it to promote digestion, be suitable for prevention and/or treatment
The diseases such as gastrointestinal motivity deficiency, abdominal distension diarrhea, indigestion, further, since used primary raw material longan total phenol extract
Plant longan from integration of drinking and medicinal herbs, therefore toxic side effect is small, safety is higher, extracts total phenol using longan pericarp, extends dragon
The application value of eye is not only conducive to environmental protection, reduces waste pollution, and reduce the processing cost of longan pericarp, realizes
The huge proliferation of economic benefit.
Present invention employs above-mentioned technical proposals to provide model essay, compensates for the deficiencies in the prior art, design is reasonable, operation side
Just.
Detailed description of the invention
For above and other purpose, feature, advantage and embodiment of the invention can be clearer and more comprehensible, appended attached drawing is said
It is bright as follows:
Fig. 1 is the structural formula schematic diagram of the curcumin phosplate of the invention；
Fig. 2 is gallic acid standard curve schematic diagram of the invention；
Fig. 3 is composition of the invention to mouse small intestine carbon powder propulsion rate schematic diagram.
Specific embodiment
Unless otherwise defined, technical and scientific term used herein has ordinary skill of the art
The identical meaning that personnel are generally understood.The present invention uses method described herein and material；But as is generally known in the art
Other suitable methods and material can also be used.Material, method and example described herein are merely illustrative,
It is not intended for limiting.All publications, patent application case, Patent Case, Provisional Application, data base entries and herein
Other bibliography referred to etc., entirety is incorporated herein as reference.It include being defined as with this specification if there is conflict
It is quasi-.
By following detailed description, attached drawing and claim, other features and advantages of the present invention be will become apparent.
In the present specification, term " extract " or " plant extracts " refer to by being divided with one or more extractive techniques
From or active constituent needed for purifying and the concentrate formulation of vegetable material that obtains.The example of extractive technique includes but is not limited to solvent
It extracts, such as, but not limited to uses water, ethyl alcohol, methanol, water/alcohol mixture, water/carbinol mixture, ethyl acetate, chromatography
Deng extraction.
In the present specification, term " drug effect effective quantity " refers in the reasonable determination range of technical staff, and such as part is applied
With or the compound or composition of systemic administration active material etc be enough significantly to induce the positive beneficial effect (such as treat
Indigestion) but down to being enough to avoid the amount of serious side effects, that is, the amount of reasonable effective hazard ratio is provided.
For words and phrases " such as " (" for example ") and " such as " (" such as ") and its grammatical equivalents, phrase " and
It is not limited to " (" and without limitation ") should be understood to follow common usage, unless expressly stated otherwise,.Such as this
Used in text, words and phrases " about " (" about ") refer in view of the variation due to experimental error.Unless expressly stated otherwise, this paper institute
All measurements stated, clearly use regardless of whether having, and will be understood to be corrected by words and phrases " about " word.Such as this paper institute
With singular " one ", "one" and "the" (" a, " " an, " and " the ") all include plural usage, unless the context otherwise
Clear stipulaties.
Embodiment 1:
The present embodiment provides a kind of longan total phenol extract, preparation method is specifically included:
One extraction step: being to mix fresh longan pericarp dry powder with the ethanol water containing piperidines ionic liquid
Even, extraction, filtering obtain filtrate；
One separating step: being to be separated by solid-liquid separation the filtrate, muddy portion's fertilizer and/or feed, obtains supernatant；
One purification step: being that the supernatant is carried out column chromatographic purifying to obtain eluent；
One concentration step: being by eluent concentration, drying to obtain longan total phenol extract.
This preferred embodiment is defined below:
In the extraction step, the fresh longan pericarp dry powder is to cross 160 after dry, pulverize after the cleaning of fresh longan pericarp
The dry powder of mesh gained；
In the extraction step, the content of ethyl alcohol is 22wt% in the ethanol water；
In the extraction step, the piperidines ionic liquid is N- butyl-N- methyl piperidine bromide and N- butyl-N- first
Bis- (fluoroform sulphonyl) inferior amine salts of phenylpiperidines；
In the extraction step, in the ethanol water, the content of the N- butyl-N- methyl piperidine bromide is
1.30wt%；The content of bis- (fluoroform sulphonyl) inferior amine salts of N- butyl-N- methyl piperidine is 0.26wt%；
In the extraction step, the material of fresh the longan pericarp dry powder and the ethanol water containing piperidines ionic liquid
Liquor ratio is 1:40, g/mL；
In the extraction step, the extracting condition is: extraction temperature is 20 DEG C, extraction time is 2h, and filter is taken after filtering
Slag repeats to extract, merging filtrate after extraction 4 times；
In the separating step, the mode of the separation of solid and liquid is to be centrifuged the filtrate to be separated by solid-liquid separation to realize；
In the separating step, it is described centrifugation for 15 DEG C at a temperature of with 15000r/min revolving speed be centrifuged 30min；
In the purification step, the eluent is the second containing piperidines ionic liquid in the extraction step
Alcohol solution；
In the purification step, the condition of the column chromatographic purifying is: loading rate is 3.0BV/h, the eluent
Flow velocity is 6.0BV/h, and elution time is 1h；
In the purification step, the concentration, drying are by the extract eluent in vacuum degree 20KPa, heating bath
Be concentrated under reduced pressure under conditions of 40 DEG C of temperature and 5 DEG C of cooling water temperature, obtained phegma be spray-dried, obtain with
Longan total phenol extract based on polymer polyphenol.
Embodiment 2:
Embodiment 2 is substantially the same manner as Example 1, the difference is that in ethanol water described in this example, the N- fourth
Base-N- methyl piperidine bromide and the content of bis- (fluoroform sulphonyl) inferior amine salts of the N- butyl-N- methyl piperidine are
1.30wt% also elutes supernatant with ethanol water described in this example.
Embodiment 3:
Embodiment 3 is substantially the same manner as Example 1, the difference is that in ethanol water described in this example, the N- fourth
Base-N- methyl piperidine bromide and the content of bis- (fluoroform sulphonyl) inferior amine salts of the N- butyl-N- methyl piperidine are
0.26wt% also elutes supernatant with ethanol water described in this example.
Comparative Example V 4:
Comparative Example V 4 is substantially the same manner as Example 1, the difference is that containing only in ethanol water described in this example
There is N- butyl-N- methyl piperidine bromide described in 1.30wt%, also supernatant is eluted with ethanol water described in this example.
Comparative Example V 5:
Comparative Example V 5 is substantially the same manner as Example 1, the difference is that containing only in ethanol water described in this example
There is N- butyl-N- methyl piperidine bromide described in 0.26wt%, also supernatant is eluted with ethanol water described in this example.
Comparative Example V 6:
Comparative Example V 6 is substantially the same manner as Example 1, the difference is that containing only in ethanol water described in this example
There are bis- (fluoroform sulphonyl) inferior amine salts of N- butyl-N- methyl piperidine described in 1.30wt%, it is also water-soluble with ethyl alcohol described in this example
Liquid elutes supernatant.
Comparative Example V 7:
Comparative Example V 7 is substantially the same manner as Example 1, the difference is that containing only in ethanol water described in this example
There are bis- (fluoroform sulphonyl) inferior amine salts of N- butyl-N- methyl piperidine described in 0.26wt%, it is also water-soluble with ethyl alcohol described in this example
Liquid elutes supernatant.
Comparative Example V 8:
Comparative Example V 8 is substantially the same manner as Example 1, the difference is that not adding in ethanol water described in this example
Add the N- butyl-N- methyl piperidine bromide and bis- (fluoroform sulphonyl) inferior amine salts of the N- butyl-N- methyl piperidine, also with
Ethanol water described in this example elutes supernatant.
Comparative Example V 9:
Comparative Example V 9 is substantially the same manner as Example 1, the difference is that containing only in ethanol water described in this example
There is 1.30wt% ethyl acetate, also supernatant is eluted with ethanol water described in this example.
Comparative Example V 10:
Comparative Example V 10 is substantially the same manner as Example 1, the difference is that containing only in ethanol water described in this example
There is 1.30wt% acetic acid, also supernatant is eluted with ethanol water described in this example.
Experimental example 1:
Respectively to longan total phenol extract degree of the progress polyphenol content in 4~V10 of Examples 1 to 3 and Comparative Example V
Measurement, the method is as follows:
A, the drafting of the content measuring standard curve of polyphenol is referring to Folin-Phenol colorimetric method, compound concentration 20,30,40,
50, the gallic acid standard solution of 60,70,80,90,100 μ g/mL, accurate each standard solution 0.1mL of measurement is placed in 10 respectively
In test tube, the forint phenol reagent of 0.5mL and the water of 7.9mL is added, after reacting 5min, adds the 1g/L sodium carbonate liquor of 1.5mL, keeps away
Light measures light absorption value after placing 2h at 765nm, draws standard curve as shown in Figure 1, obtaining regression equation is Y=0.0105X+
0.1745, R2=0.9992 (concentration range is 20~100 μ g/mL).
B, each example longan total phenol extract is configured to the sample solution of 10mg/mL, precision measures sample solution 0.1mL and sets
In test tube, light absorption value is measured after handling according to the above method, by standard curve regression equation calculation longan Determination of Polyphenols, as a result
(mg/g) is indicated with the milligram number for containing suitable gallic acid in every gram of longan pericarp.Statistical result is as shown in table 1.
Polyphenol content and polyphenol recovery rate count in table 1, longan total phenol extract
| Embodiment | 1 | 2 | 3 | V4 | V5 | V6 | V7 | V8 | V9 | V10 |
| Content % | 92.5 | 89.5 | 85.2 | 70.6 | 72.3 | 71.2 | 71.5 | 55.6 | 62.0 | 65.5 |
| Recovery rate mg/g | 35.6 | 34.4 | 32.8 | 27.3 | 27.5 | 27.4 | 27.9 | 22.5 | 24.3 | 26.5 |
As shown in Table 1, in the preferred embodiment of the present invention 1, polyphenol content reaches in longan total phenol extract
92.5%, and polyphenol recovery rate has also reached 35.6mg/g, even if being not preferred in the embodiment 2 and embodiment 3 of embodiment
Corresponding polyphenol content has also exceeded 85%, and polyphenol recovery rate has also exceeded 32mg/g, considerably beyond the phase of comparative example
Answer data, it is seen that the present invention is very high to the extraction efficiency of total phenol in longan pericarp, greatly improves longan pericarp regeneration
Economic value, higher purity and recovery rate can also assign the efficient physiology effect of longan total phenol extract and medical value.
Embodiment 11:
The present embodiment provides a kind of oligomeric saccharide complex of curcumin phosplate, preparation methods are as follows:
Obtain the oligomeric sugar aqueous solution of 5 DEG C, 12wt%；
Obtain the alcoholic solution of 5 DEG C, the curcumin phosplate of 6wt%；
Curcumin phosplate solution is injected in oligosaccharide solution under stirring；
It is spray-dried immediately after the completion of injection up to the oligomeric saccharide complex of water-soluble curcumin.
This preferred embodiment further limits as follows:
The stirring condition is 190r/min.
The injection rate is 4mL/min.
The content of ethyl alcohol is 45% in the alcoholic solution.
The spray drying condition is: 220 DEG C of inlet air temperature, 68 DEG C of leaving air temp, and negative pressure of vacuum=- 0.06Mpa, product
Moisture=0.5%.
In the application, the curcumin phosplate, which is dissolved in alcohol, forms solution, and the solution is molten in inflow oligosaccharide
When in liquid, due to the reduction of alcohol concentration, curcumin phosplate is micro- with nanoscale in the conversion process of liquid phase and solid phase
Size separation goes out, and at this moment, the group in group and oligosaccharide in curcumin phosplate passes through spray with hydrogen bond formation physical bond
Mist is dry and solidifies, and forms the oligomeric saccharide complex of water-soluble curcumin phosplate, the ginger in this solid composite dispersion
Flavine phosplate solubility significantly improves.
Embodiment 12~20:
Embodiment 12~20 provides a kind of composition respectively, each component in the composition and its occupies the composition
Weight percent it is as shown in table 2.
Each component in table 2, embodiment 1 and the composition of embodiment 12~20
Note: in upper table, " commercially available " to indicate the sodium alginate from commercially available, the sodium alginate is prepared by brown alga
It arrives, is straight chain type, beta-D-mannuronic acid unit/α-L- guluronic units molar ratio=1.5 in structure；"/" indicates
It is 0 without this and content.
Experimental example 2:
Carrying out mouse enterocinesia to each composition in above-described embodiment 1 and embodiment 12~20 influences experiment, specifically such as
Under:
A, healthy mice 55,6~8 week old, half male and half female, 18~22g of weight, conventional feed are fed, in control room
Environmental condition is relative humidity 50% and 18~24 DEG C of temperature, for testing after adaptability conventinal breeding 1 week.Mouse is divided at random
It is following 11 groups: blank control group (C group), treatment group (P1, P12, P13, P14, P15, P16, P17, P18, P19, P20, difference
Corresponding embodiment 1 and embodiment 12~20), every group 5.Experiment starts preceding each group for 24 hours and is deprived of food but not water, and after experiment starts, removes
Blank control group is given outside physiological saline, and composition is given in other each treatment group's stomach-fillings, dosage be 5mg/10g weight (with
It is administered after physiological saline solution).
B, after 30min being administered, the equal stomach-filling of each group mouse is given containing 1% sodium carboxymethylcellulose and containing 5% activated carbon powder
Suspension, giving volume is 0.1mL/10g weight.Cervical dislocation puts to death mouse after 30min, takes out from pylorus to ileocecus
Whole section of small intestine, gently pulled into straight line, measure small intestine overall length and distance that carbon powder forward position is promoted in small enteral, count as the following formula
Calculate mouse small intestine carbon powder propulsion rate: small intestine carbon powder propulsion rate=carbon powder promotes length/total small intestinal length × 100% in small intestine,
And it is as shown in Figure 3 to arrange result.
From the figure 3, it may be seen that pre-selection embodiment 1 (total phenol of longan containing the 80wt% extract, 10wt% curcumin list phosphorus of the application
The oligomeric saccharide complex of acid esters and 10wt% sodium alginate) in composition to enterocinesia effect synergy it is significant, carbon powder propulsion rate
It is greatly enhanced, relative to certain in a certain ingredient or combined administration composition being used alone in composition
Two kinds of ingredients have the significant difference on statistical significance, illustrate three kinds of total phenol extractions of component longan in the composition of the application
Object, the oligomeric saccharide complex of curcumin phosplate and sodium alginate are used cooperatively with positive promotion digestion, promote stomach compacted
Dynamic effect, further can effectively protect stomach lining, improve gastrointestinal motivity, improve indigestion, can with its replace domperidone,
The drugs such as mosapride citrate play it and promote digestion, the insufficient, abdominal distension suitable for prevention and/or treatment gastrointestinal motivity
The diseases such as diarrhea, indigestion, toxic side effect is small, and safety is higher.
The prior art of routine techniques dawn known to those skilled in the art in above-described embodiment, therefore herein no longer in detail
It repeats.
The above embodiments are only used to illustrate the present invention, and not limitation of the present invention, the ordinary skill people of this field
Member can also make a variety of changes and modification without departing from the spirit and scope of the present invention.Therefore, all equivalent
Technical solution also belong to scope of the invention, scope of patent protection of the invention should be defined by the claims.
Claims (10)
1. a kind of rush digests composition, it is characterised in that the composition includes:
Longan total phenol extract；
The oligomeric saccharide complex of curcumin phosplate；And
Alginic acid or its salt；
Wherein, the longan total phenol extract is so that the ethanol water containing piperidines ionic liquid extracts longan peel and obtains
It arrives.
2. composition according to claim 1, it is characterised in that: the preparation of the longan total phenol extract in the composition
At least step that method includes the following steps:
One extraction step: being to be uniformly mixed fresh longan pericarp dry powder with the ethanol water containing piperidines ionic liquid, leaching
It mentions, filter acquisition filtrate；
One separating step: being to be separated by solid-liquid separation the filtrate, muddy portion's fertilizer and/or feed, obtains supernatant；
One purification step: being that the supernatant is carried out column chromatographic purifying to obtain eluent；
One concentration step: being by eluent concentration, drying to obtain longan total phenol extract.
3. composition according to claim 1 or 2, it is characterised in that: the piperidines ionic liquid is N- butyl-N- first
Phenylpiperidines bromide and bis- (fluoroform sulphonyl) inferior amine salts of N- butyl-N- methyl piperidine.
4. composition according to claim 1 or 2, it is characterised in that: in the ethanol water, contain
N- butyl-N- methyl piperidine the bromide of 1.25~1.3wt%；With
Bis- (fluoroform sulphonyl) inferior amine salts of the N- butyl-N- methyl piperidine of 0.25~0.26wt%.
5. composition according to claim 2, it is characterised in that: in the purification step, in the extraction step
The ethanol water containing piperidines ionic liquid elutes the supernatant.
6. composition according to claim 1, it is characterised in that: the curcumin list phosphorus in the composition in the composition
The preparation method of the oligomeric saccharide complex of acid esters includes:
Obtain the oligomeric sugar aqueous solution of 1~10 DEG C, 10~35wt%；
Obtain the alcoholic solution of 1~10 DEG C, the curcumin phosplate of 3~8wt%；
Curcumin phosplate solution is injected in oligosaccharide solution under stirring；
It is spray-dried immediately after the completion of injection up to the oligomeric saccharide complex of water-soluble curcumin.
7. composition according to claim 1, it is characterised in that: the alginic acid or its salt in the composition meet
At least one of below:
The alginic acid or its salt are prepared by brown alga；
The alginic acid or its salt are straight chain type；
Beta-D-mannuronic acid unit/α-L- guluronic units molar ratio=1.5 in the alginic acid or its salt；
The alginate is sodium alginate.
8. the preparation method of any one of claim 1~7 composition, characterized by comprising: by alginic acid or its salinity
It dissipates in solvent, is prepared into the solution that concentration is 3wt%；Sequentially add the oligomeric saccharide complex of curcumin and the total phenol extraction of longan
Object, mixed solution ultrasonic treatment 1h, low temperature are concentrated into density between 1.001~1.300g/mL to obtain the final product.
9. a kind of pharmaceutical composition for promoting digestion, it is characterised in that described pharmaceutical composition includes that a effective amount of right of drug effect is wanted
Seek any one of 1~7 composition.
10. the application of any one of claim 1~7 composition, characterized by comprising:
The composition is preventing and/or is treating the application in gastrointestinal motivity deficiency；And/or
Application of the composition in preparation prevention and/or the treatment insufficient pharmaceutical preparation of gastrointestinal motivity；And/or
The composition is preventing and/or is treating the application in mucosal lesion；And/or
Application of the composition in the preparation of preparation prevention and/or treatment mucosal lesion drug；And/or
The composition is preventing and/or is treating the application in indigestion；And/or
The composition prevents and/or treats the application in dyspeptic pharmaceutical preparation in preparation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910444716.3A CN110151854A (en) | 2019-05-27 | 2019-05-27 | Rush digestion composition, preparation method and application containing longan total phenol extract |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910444716.3A CN110151854A (en) | 2019-05-27 | 2019-05-27 | Rush digestion composition, preparation method and application containing longan total phenol extract |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110151854A true CN110151854A (en) | 2019-08-23 |
Family
ID=67632886
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910444716.3A Withdrawn CN110151854A (en) | 2019-05-27 | 2019-05-27 | Rush digestion composition, preparation method and application containing longan total phenol extract |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110151854A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110862338A (en) * | 2019-11-21 | 2020-03-06 | 珠海中科先进技术研究院有限公司 | Preparation method and application of stachydrine ionic liquid |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104547206A (en) * | 2014-12-23 | 2015-04-29 | 东北大学 | Longan pericarp extract as well as extracting method, composition and application thereof |
| CN108174944A (en) * | 2017-12-13 | 2018-06-19 | 华侨大学 | Utilize the method for tea polyphenols in ionic liquid auxiliary aqueous two-phase system extraction tea grounds |
| CN109589311A (en) * | 2018-12-29 | 2019-04-09 | 山东大学 | Pharmaceutical composition, preparation and the preparation method and medical usage of a kind of curcumin phosplate and its salt |
| CN109675089A (en) * | 2019-02-28 | 2019-04-26 | 四川大学 | Promote the biologic bracket material and its preparation method and application of skin wound healing |
| CN109674054A (en) * | 2019-01-25 | 2019-04-26 | 龙岩市启明投资有限公司 | A kind of preparation method of the oligomeric saccharide complex of water solubility curcumin and its solid beverage |
| CN109731037A (en) * | 2019-03-22 | 2019-05-10 | 中南大学湘雅医院 | A kind of pharmaceutical composition and its application promoting gastrointestinal peristalsis |
-
2019
- 2019-05-27 CN CN201910444716.3A patent/CN110151854A/en not_active Withdrawn
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104547206A (en) * | 2014-12-23 | 2015-04-29 | 东北大学 | Longan pericarp extract as well as extracting method, composition and application thereof |
| CN108174944A (en) * | 2017-12-13 | 2018-06-19 | 华侨大学 | Utilize the method for tea polyphenols in ionic liquid auxiliary aqueous two-phase system extraction tea grounds |
| CN109589311A (en) * | 2018-12-29 | 2019-04-09 | 山东大学 | Pharmaceutical composition, preparation and the preparation method and medical usage of a kind of curcumin phosplate and its salt |
| CN109674054A (en) * | 2019-01-25 | 2019-04-26 | 龙岩市启明投资有限公司 | A kind of preparation method of the oligomeric saccharide complex of water solubility curcumin and its solid beverage |
| CN109675089A (en) * | 2019-02-28 | 2019-04-26 | 四川大学 | Promote the biologic bracket material and its preparation method and application of skin wound healing |
| CN109731037A (en) * | 2019-03-22 | 2019-05-10 | 中南大学湘雅医院 | A kind of pharmaceutical composition and its application promoting gastrointestinal peristalsis |
Non-Patent Citations (4)
| Title |
|---|
| 唐瑶等: ""多酚类化合物的分类、来源及功能研究进展"", 《中国食物与营养》 * |
| 李建颖: "《食品添加剂速查手册》", 30 November 2017, 南开大学出版社 * |
| 许海棠等: ""百香果叶总酚的提取工艺优化、抗氧化活性及其抑制α-葡萄糖苷酶活性"", 《食品工业科技》 * |
| 郭志丽等: ""姜黄素灌胃不同时间和剂量对小鼠胃肠蠕动的影响"", 《中国儿童保健杂志》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110862338A (en) * | 2019-11-21 | 2020-03-06 | 珠海中科先进技术研究院有限公司 | Preparation method and application of stachydrine ionic liquid |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN113150867B (en) | Preparation method of ganoderma lucidum extract oil rich in ganoderma lucidum triterpenes | |
| CN110367581A (en) | It is a kind of by industrial hemp extract the ingredient containing cannabinoids composition and its purposes in tobacco product | |
| WO2017128941A1 (en) | Bamboo leaf extract and preparation method and use thereof | |
| CN110663788A (en) | Tea extract and industrial preparation method and application thereof | |
| CN101120950A (en) | Application of realgar microorganism extracting liquid in preparing anti-tumor medicine | |
| CN110151854A (en) | Rush digestion composition, preparation method and application containing longan total phenol extract | |
| CN104739726B (en) | A kind of Chinese medicine toothpaste and preparation method thereof | |
| CN104739960B (en) | Stomach antibacterial combination, the stomach antibacterials containing said composition and preparation | |
| CN115531463B (en) | Traditional Chinese medicine for treating hyperlipidemia | |
| CN106420919A (en) | Preparation method and application of Nepeta bracteatatotal flavonoids | |
| CN101024663A (en) | Novel compound, extract containing same and its preparing method and use | |
| CN100370993C (en) | Medicinal composition with heat-clearing, fire-draining and detoxification function | |
| CN104208089B (en) | Gastric floating preparation for treating poultry proventriculitis and preparation method thereof | |
| CN113797235A (en) | Preparation method of compound ganoderma lucidum spore oil with liver protection effect | |
| CN101085037A (en) | Traditional Chinese medicine preparation for animals and preparation method thereof | |
| CN101919903B (en) | Method for preparing rabdosia rubescens diterpene extract | |
| CN106138665A (en) | A kind of Chinese medicine composition for treating chicken pneumonia | |
| CN110025737A (en) | Probiotics fermention loquat composition and preparation method thereof | |
| CN104906214B (en) | The combined preparation process of flavonoids and triterpene acid in a kind of loguat leaf | |
| CN105085446A (en) | Novel ladanum type diterpene derivative and preparation method and application thereof | |
| CN115607596B (en) | Health wine with uric acid reducing effect and preparation method thereof | |
| CN102793869A (en) | Traditional Chinese medicine composition for controlling porcine viral diseases and preparation method thereof | |
| CN108743573A (en) | Fluorenes ketone compounds are preparing the application and preparation method thereof in preventing diabetes medicament in the stem of noble dendrobium | |
| CN114146142A (en) | Mulberry leaf compound extract and preparation method and application thereof | |
| CN108938749B (en) | Pharmaceutical composition and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20190823 |
|
| WW01 | Invention patent application withdrawn after publication |